The company has advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
- Status:
- Suspended
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 3879
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 January 2026 | Suspended. The company has advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 03 November 2022 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual